AOD 9604 Benefits: Dosage, Side Effects and Research

AOD-9604 is a fragment of human growth hormone studied for fat metabolism. Learn how it works, reported research doses, side effects and how it compares with tesamorelin.

Signal IQ Editorial4 min read · Updated Nov 8, 2026
AOD 9604 Benefits: Dosage, Side Effects and Research
In this article
  1. What is AOD-9604?
  2. AOD 9604 benefits: what the research suggests
  3. AOD 9604 before and after: what to expect
  4. AOD 9604 dosage per day
  5. AOD 9604 side effects
  6. AOD 9604 vs full growth hormone
  7. AOD 9604 vs tesamorelin
  8. Frequently asked questions

The reported benefits of AOD-9604 centre on fat metabolism: it is a fragment of human growth hormone (amino acids 176 to 191) that was isolated to stimulate fat breakdown without the wider hormonal effects of full-length growth hormone. Preclinical findings are encouraging, but evidence for meaningful weight loss in humans is much less definitive, and it is not approved for human use.

Key takeaways
  • AOD-9604 corresponds to the fat-metabolism region of human growth hormone and was developed at Monash University.
  • It is reported to promote lipolysis and inhibit lipogenesis with minimal IGF-1 or glucose effect.
  • Research protocols list 250 to 500 mcg once daily, usually in a 12 to 16 week cycle.
  • Human evidence for weight loss is limited; it is a research compound, not an approved drug.

What is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide that mirrors the C-terminal end of human growth hormone. That region is the part associated with fat metabolism; the IGF-1 stimulation, glucose effects and growth-promoting activity of growth hormone come from other parts of the molecule.

The aim was a targeted compound that keeps growth hormone’s lipolytic effect without its broader hormonal action. See the AOD-9604 research profile for mechanism and key studies.

AOD 9604 benefits: what the research suggests

Two actions are usually cited for AOD-9604:

  • Increased lipolysis: fat cells release stored fatty acids for use as fuel. The mechanism involves beta-3 adrenergic receptors and partial agonism at the growth hormone receptor.
  • Reduced lipogenesis: dietary fat is less readily converted into stored body fat.

Studies also report minimal IGF-1 stimulation and minimal glucose impact compared with full growth hormone. Muscle-building effect is described as negligible. The strongest data are preclinical, and the claim of significant human weight loss is considerably less well supported.

AOD 9604 before and after: what to expect

Reports describe a slow, cumulative effect, not a rapid change. The first weeks usually show little visible difference. Gradual shifts in body composition are described over several weeks, often in the abdominal region first, with clothing fit changing before the scale does.

These accounts are not controlled trial data. AOD-9604 is not described as producing dramatic standalone results without a calorie deficit.

AOD 9604 dosage per day

The Signal IQ AOD-9604 page lists two research ranges, both given once daily in the morning by subcutaneous injection.

RangeReported amountSyringe unitsSuggested cycle
Lower / maintenance250 mcg per day10 units12 to 16 weeks on, 2 to 4 weeks off
Higher500 mcg per day20 units12 to 16 weeks on, 2 to 4 weeks off

Morning use is common, and a fasted state is often incorporated, although the evidence that fasting is required is limited. The unit counts assume a particular mix, so confirm the concentration of your own vial; the arithmetic is explained in how to reconstitute peptides. For all compounds side by side, see the peptide dosage chart.

Note: These are ranges reported in research protocols, not personal recommendations. AOD-9604 is not approved for human use; discuss any decision with a qualified clinician. See peptide cycling for background on on/off periods.

AOD 9604 side effects

Reported effects are generally mild:

  • Injection-site redness or bruising, common and temporary
  • Headache in a minority during the first week
  • Occasional fatigue, mainly at higher amounts

Sources describe no significant thyroid, insulin or IGF-1 disruption at standard amounts, and note that the compound received GRAS status from the FDA as a food ingredient during development. That status is about a food-ingredient context, not approval as a drug. Systematic long-term human safety data are limited. A broader overview is in peptide side effects.

AOD 9604 vs full growth hormone

FactorAOD-9604Full growth hormone
Fat-loss mechanismDirect, from the 176 to 191 regionDirect plus indirect via IGF-1
IGF-1 stimulationMinimalSignificant
Glucose effectMinimalInsulin resistance possible at higher doses
Carpal tunnel / oedemaRareCommon at higher doses
Muscle buildingNegligibleYes, via IGF-1

AOD 9604 vs tesamorelin

AOD-9604 acts directly on fat cells, whereas tesamorelin is a growth hormone releasing hormone analog that stimulates the body’s own growth hormone release. The two work through different routes, which is why some research discussions treat them as complementary rather than interchangeable.

Tesamorelin raises growth hormone and therefore involves IGF-1, so periodic IGF-1 monitoring is relevant to it in a way it is not for AOD-9604. For more on that class, see ipamorelin vs sermorelin vs tesamorelin and peptides for weight loss.

Frequently asked questions

What are the benefits of AOD 9604?

It is studied for stimulating fat breakdown and reducing fat storage with minimal IGF-1 or glucose effect. Human evidence for weight loss is limited.

What is a typical AOD 9604 dosage per day?

Research protocols list 250 to 500 mcg once daily in the morning, in cycles of 12 to 16 weeks on and 2 to 4 weeks off. This is not a recommendation.

Does AOD 9604 have side effects?

Mild ones are reported: injection-site redness, early headache and occasional fatigue. Long-term human data are limited.

Does AOD 9604 need to be taken fasted?

A fasted state is often used, but evidence that it is required is limited.

Is AOD 9604 FDA-approved?

No. It is a research compound, and its GRAS status related to use as a food ingredient, not as a drug.

Go deeper on Signal IQ

Dosing & protocolAOD-9604Research profileAOD-9604

Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.

Ask Pulse

Educational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.

Keep reading